Developing personalized treatments for glioblastoma using single-cell analysis
Official title: A multimodal single-cell approach to developing personalized combinatorial treatments for glioblastoma
Funded at Massachusetts General Hospital · NIH-11013886 · Data updated 2026-11-12
This study is looking at glioblastoma, a tough type of brain cancer, to find out how different tumor cells react to different drug combinations, with the goal of discovering the best treatments for each person's unique tumor.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 22, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $140,531 |
| NIH project number | 5R21CA286215-02 |
| Project ID | NIH-11013886 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a complex brain cancer characterized by diverse tumor cell types. By utilizing advanced techniques like single-cell RNA sequencing and flow sorting, the study aims to isolate different tumor cell populations and assess their responses to various drug combinations. This personalized approach seeks to identify the most effective treatments tailored to the unique characteristics of each patient's tumor, potentially improving outcomes for those affected by this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with glioblastoma.
How similar studies have gone: Previous research has shown promise in using single-cell analysis for cancer treatment, indicating that this approach could lead to significant advancements in personalized medicine.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Petti, Allegra Adele — Massachusetts General Hospital
- Study coordinator: Petti, Allegra Adele
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.